The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Lodoxamida     [3-(carboxycarbonylamino)-2- chloro-5-cyano...

Synonyms: Lodoxamide, Lodoxamidum, Alomide (TN), SureCN119881, CHEMBL1201266, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Lodoxamide

 

High impact information on Lodoxamide

 

Chemical compound and disease context of Lodoxamide

 

Biological context of Lodoxamide

  • Those subjects demonstrating a protective effect of lodoxamide subsequently underwent antigen inhalation challenges at various time intervals (2 to 8 hr) after lodoxamide treatment [9].
  • Lodoxamide was highly effective, as judged by the absence of both overt signs and characteristic post-DEC changes in platelet numbers, serum fibrinogen level, and serum transaminase (SGOT, SGPT) levels, in blocking the reaction in dogs with a microfilaremia level that would make them moderately reactive [15].
  • Furthermore, the inhibitory effects of FR50948 on type III reactions and inflammatory reactions were much more potent than those of SCG and equal to those of lodoxamide, and the effect on IgG-mediated PCA was stronger than that of either reference drug [16].
  • RESULTS: Only levacobastine and lodoxamide decreased vascular permeability at a significant ratio (46%, p < 0.01 and 31%, p < 0.05, respectively) [17].
  • Although infusion of 1.0 microgram per 100 g b.w. serotonin and/or 10 micrograms per 100 g b.w. lodoxamide produced no change in arterial blood pressure, 10 or 20 micrograms per 100 g b.w. serotonin evoked hypotension within 40 sec [18].
 

Anatomical context of Lodoxamide

 

Associations of Lodoxamide with other chemical compounds

 

Gene context of Lodoxamide

 

Analytical, diagnostic and therapeutic context of Lodoxamide

  • All subjects underwent antigen inhalation challenge 15 min after inhalation of an aerosolized solution of 0.1 mg of lodoxamide in saline or of saline solution alone (placebo) administered on separate days according to a double-blind, random-allocation protocol [9].
  • Determination of lodoxamide in plasma using ion-pairing and reversed-phase high-performance liquid chromatography [29].
  • Lodoxamide produced a significant reduction in ultimate infarct size measured at 24 h by postmortem tetrazolium perfusion staining [21].
  • Albumin concentrations in lavage fluid (BAL) of lodoxamide-treated animals were 243 +/- 165 micrograms/ml in right lung and 29 +/- 15 micrograms/ml in left lung (p less than 0.03); albumin concentration in right lung BAL of untreated animals was 1,180 +/- 319 micrograms/ml (p less than 0.02 vs. lodoxamide-treated animals) [30].
  • After treatment with lodoxamide 0.1%, tear LTB4 and LTC4 levels of the OP-GPC patients decreased significantly [31].

References

  1. The protective effect of lodoxamide on antigen-induced bronchospasm. An orally active antiallergic drug. Case, R.L., Rogers, P.B., VanArsdel, P.P., Altman, L.C. JAMA (1982) [Pubmed]
  2. Effect of lodoxamide on the secretory response induced by Escherichia coli and Vibrio cholerae enterotoxins in infant mice. Knoop, F.C., Thomas, D.D. Infect. Immun. (1984) [Pubmed]
  3. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Avunduk, A.M., Avunduk, M.C., Kapicioglu, Z., Akyol, N., Tavli, L. Ophthalmology (2000) [Pubmed]
  4. A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. Hannon, J.P., Pfannkuche, H.J., Fozard, J.R. Br. J. Pharmacol. (1995) [Pubmed]
  5. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats. Yanni, J.M., Weimer, L.K., Glaser, R.L., Lang, L.S., Robertson, S.M., Spellman, J.M. Int. Arch. Allergy Immunol. (1993) [Pubmed]
  6. Clostridium difficile toxin A-induced microvascular dysfunction. Role of histamine. Kurose, I., Pothoulakis, C., LaMont, J.T., Anderson, D.C., Paulson, J.C., Miyasaka, M., Wolf, R., Granger, D.N. J. Clin. Invest. (1994) [Pubmed]
  7. Enhanced mucosal permeability and nitric oxide synthase activity in jejunum of mast cell deficient mice. Komatsu, S., Grisham, M.B., Russell, J.M., Granger, D.N. Gut (1997) [Pubmed]
  8. The role of mast cells in ischaemia-reperfusion injury in murine skeletal muscle. Lazarus, B., Messina, A., Barker, J.E., Hurley, J.V., Romeo, R., Morrison, W.A., Knight, K.R. J. Pathol. (2000) [Pubmed]
  9. Effect of inhaled iodoxamide tromethamine in prevention of antigen-induced bronchospasm. Ungerer, R.G., Tashkin, D.P., Siegel, S.C., Deutsch, R.I. J. Allergy Clin. Immunol. (1981) [Pubmed]
  10. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Bonini, S., Schiavone, M., Bonini, S., Magrini, L., Lischetti, P., Lambiase, A., Bucci, M.G. Ophthalmology (1997) [Pubmed]
  11. Comparative effectiveness and molecular pharmacological mechanisms of antiallergic agents on experimental conjunctivitis in mice. Hu, S., Merayo-Lloves, J., Zhao, T., Foster, C.S. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (1998) [Pubmed]
  12. Allopurinol and lodoxamide in complement-induced hepatic ischemia. Schirmer, W.J., Schirmer, J.M., Naff, G.B., Fry, D.E. J. Surg. Res. (1988) [Pubmed]
  13. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Richard, C., Trinquand, C., Bloch-Michel, E. European journal of ophthalmology. (1998) [Pubmed]
  14. Hepatic microvascular regulatory mechanisms. IV. Effect of lodoxamide tromethamine and arterenol-HCl on vascular responses evoked by compound 48/80. Reilly, F.D., Dimlich, R.V. Microcirculation, endothelium, and lymphatics. (1984) [Pubmed]
  15. Inhibition of the adverse reaction to diethylcarbamazine in Dirofilaria immitis-infected dogs by lodoxamide ethyl. Desowitz, R.S., Palumbo, N.E., Perri, S.F., Sylvester, M.S. Am. J. Trop. Med. Hyg. (1982) [Pubmed]
  16. Effects of FR50948, a new orally active antiallergic agent, in experimental allergic models. Hiroi, J., Ohara, K., Kobayashi, K., Fujitsu, T., Fujii, T., Motoyama, Y., Mori, J., Shibayama, F. Jpn. J. Pharmacol. (1988) [Pubmed]
  17. Comparison of antiallergic drugs in an experimental model of ocular anaphylaxis. Bayer, A., Uludağ, H.A., Sobaci, G., Mutlu, F.M. Ophthalmologica (2003) [Pubmed]
  18. Hepatic microvascular regulatory mechanisms. V. Effects of lodoxamide tromethamine or phentolamine-HCl on vascular responses elicited by serotonin. Reilly, F.D., Cilento, E.V., McCuskey, R.S. Microcirculation, endothelium, and lymphatics. (1984) [Pubmed]
  19. Effects of lodoxamide tromethamine on paraplegia that occurs after infrarenal aortic occlusion in the rabbit. Ball, T.D., Lundy, E.F., Zelenock, G.B., D'Alecy, L.G. J. Vasc. Surg. (1987) [Pubmed]
  20. Antiallergic activity of topical lodoxamide on in vivo and in vitro models. Ciprandi, G., Buscaglia, S., Catrullo, A., Paolieri, F., Riccio, A.M., Fiorino, N., Canonica, G.W. Allergy (1996) [Pubmed]
  21. Effects of lodoxamide on ischemic reperfused myocardium. Jolly, S.R., Abrams, G.D., Romson, J.L., Bailie, M.B., Lucchesi, B.R. J. Cardiovasc. Pharmacol. (1982) [Pubmed]
  22. Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors. Maruyama, R., Hatta, E., Yasuda, K., Smith, N.C., Levi, R. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  23. Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. Schoch, C. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2003) [Pubmed]
  24. Acute pulmonary response to cotton bract extract in monkeys: lung function and effects of mediator modifying compounds. Witek, T.J., Gundel, R.H., Wegner, C.D., Schachter, E.N., Buck, M.G. Lung (1988) [Pubmed]
  25. Neuroimmune mechanisms of intestinal responses to stress. Role of corticotropin-releasing factor and neurotensin. Pothoulakis, C., Castagliuolo, I., Leeman, S.E. Ann. N. Y. Acad. Sci. (1998) [Pubmed]
  26. Inhibitory effects of lodoxamide on eosinophil activation. Capron, M., Loiseau, S., Papin, J.P., Robertson, S., Capron, A. Int. Arch. Allergy Immunol. (1998) [Pubmed]
  27. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Leonardi, A., Borghesan, F., Avarello, A., Plebani, M., Secchi, A.G. The British journal of ophthalmology. (1997) [Pubmed]
  28. Ischemia/reperfusion-induced microvascular dysfunction: role of oxidants and lipid mediators. Kurose, I., Argenbright, L.W., Wolf, R., Lianxi, L., Granger, D.N. Am. J. Physiol. (1997) [Pubmed]
  29. Determination of lodoxamide in plasma using ion-pairing and reversed-phase high-performance liquid chromatography. Honigberg, I.L., Stewart, J.T., Ewing, B.J., Taylor, W.D. J. Chromatogr. (1983) [Pubmed]
  30. Lodoxamide tromethamine prevents neutrophil accumulation in reexpansion pulmonary edema. Veal, C.F., Jackson, R.M., Brannen, A.L., Fulmer, J.D. J. Cardiovasc. Pharmacol. (1989) [Pubmed]
  31. Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis. Akman, A., Irkeç, M., Orhan, M., Erdener, U. Ocul. Immunol. Inflamm. (1998) [Pubmed]
 
WikiGenes - Universities